Discover how IFLI's journey from Inception to Innovation in Follicular Lymphoma Research and Treatment is transforming patient care and outcomes
The Institute for Follicular Lymphoma Innovation(IFLI) remains steadfast in its mission to improve patient outcomes and accelerate the development of transformative therapies for follicular lymphoma. As we reflect on 2024, it has been a year of remarkable progress, marked by groundbreaking research collaborations, strategic investments, and innovative initiatives that are shaping the future of follicular lymphoma treatment.
Key Achievements in 2024
Strategic Funding for Collaborative Research
IFLI committed to over $20M in funding over the next 5 years in pivotal partnerships with leading organizations, including the Leukemia & Lymphoma Society (LLS) and the Follicular Lymphoma Foundation (FLF). These funds support large-scale grant programs such as RAFL and CureFL, which aim to discover better treatments and, ultimately, a cure for blood cancers.
Groundbreaking Research Collaborations
IFLI launched a transformative $2 million research initiative with City of Hope to study spontaneous remission in follicular lymphoma, a phenomenon that could unlock new therapeutic approaches. Additional collaborations include partnerships with Weil Cornell, Inserm-France, and Francis Crick-UK, further expanding our global research network.
Advancing Biomarker and Personalized Medicine Strategies
IFLI continued to advance its innovative Biomarker Discovery Programs, including the BIDIFLY initiative, in partnership with LYSA - Lysarc. These efforts are critical for identifying predictive biomarkers that can guide personalized treatment strategies.
IFLI initiated a collaboration with Tempus to leverage AI-driven insights to accelerate the development of FL treatments. The project will focus on prospectively generating multimodal FL data, as well as ingesting and harmonizing existing datasets into a centralized data ecosystem, particularly for POD24 FL patients – those who experience disease progression within 24 months of treatment.
Minimal Residual Disease (MRD) Research
IFLI is at the forefront of MRD research, supporting two pivotal projects: A $2.1 million, four-year collaboration with Washington University to explore MRD in follicular lymphoma. An $824,000 grant was awarded to Queen Mary University of London to advance MRD research.
Strategic Biotech Partnerships and Investments
IFLI has structured key deals to accelerate therapeutic innovation: Innate Pharma: Up to $7.9 million in funding to include patients with relapsed or refractory follicular lymphoma in the Ph1/2 clinical trials for IPH6501, Innate's anti-CD20 ANKET® asset PeproMene Bio: Up to $11 million in funding to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory follicular lymphoma Verismo Therapeutics: Up to $4M in funding to support development of novel CD19-targeting SynKIR™-310 development, and expansion of follicular lymphoma patient recruitment in its Phase 1 trial focused on post-CAR T and CAR-naive relapsed/refractory B-NHL.
Looking Ahead to 2025
IFLI is committed to building on this momentum by exploring emerging technologies such as spatial proteomics and machine learning, which hold immense promise for revolutionizing follicular lymphoma research and treatment. Together, with our partners and supporters, we are driving progress toward a future where follicular lymphoma is not only treatable but curable.
.png)
Founded in February 2022, IFLI is a non-profit organization dedicated to advancing Follicular Lymphoma (FL) research and treatment. We are committed to establishing strong partnerships that enhance our understanding of FL biology and significantly impact treatment options available to patients.
.png)
Fund the best initiatives worldwide by building strong partnerships and maximizing available resources, aiming to transform Follicular Lymphoma research
Accelerate the development of innovative treatment options to extend the life expectancy of people with follicular lymphoma and ultimately develop a cure
Effectively prioritize tasks based on organization mission and goals
Show respect to others and confronts interpersonal issues directly
Prioritize resolution of partnership issues effectively
Respond promptly and honor commitments to internal and external stakeholders
Innovate and Act! Take initiative. Press hard and swiftly for progress, take risks and don’t be afraid to challenge the norms or to fail
Make recommendations to continuously improve methods, processes, and systems
Demonstrate adaptability by reacting appropriately to unexpected changes in situations or circumstances
Increase performance through greater efficiency
Seek to develop technical knowledge through learning from other experts
Understand organizational impact of individual decisions and actions
Seek solutions rather than placing blame
Tackle challenges with a sense of purpose, urgency, and determination because the disease won’t wait
Consistently look for ways to improve oneself through growth and development opportunities
Communicate clearly and promptly up, down, and across
Communicate effectively to manage expectations
IFLI is dedicated to supporting advances in understanding the biology of follicular lymphoma patients who are at high risk of progression, and accelerating the development of precision medicine to extend the median life expectancy of FL patients with early progression to ultimately develop a cure for FL.
Capital Allocations
Sponsored Agreements
Program Investments
Venture Philanthropy
Filter by:
Chief Medical Officer
IFLI
NJ, USA
.jpg){kind=avatar}
Director, Portfolio & Project Management
IFLI
CA, USA
Venture Partner
IFLI
CA, USA
Scientific Development Director
IFLI
CA, USA
Business Dev & Licensing Advisor
IFLI
NC, USA
Chairman of Development, Independent Director, Board of Directors
Centessa Pharmaceuticals, Sanofi
MA, USA
Research Director, Director
CIML Marseille, CALYM Carnot Institute
France
Professor of Medicine, Division of Oncology, Siteman Cancer Center
Washington University in St. Louis School of Medicine
MO, USA
Professor of Medicine, Clinical Oncologist
Stanford University
CA, USA
Professor of Hematology/Oncology
Weill Cornell Medical College
NY, USA
Head of Cancer Lymphoid Research
University of British Columbia
Canada
Assistant Professor, Director, Translational and Laboratory Research, Department of Lymphoma - Myeloma, Division of Cancer Medicine
MD Anderson Cancer Center
TX, USA
Assistant Professor of Pharmacology
Weill Cornell Medical College
NY, USA
Design personalized approaches to improve FL patient outcomes
Identify FL patients at high risk of progression and develop the right treatment
Promote data sharing as a catalyst of medical breakthrough
Develop & lead complementary integrated programs
Play an instrumental role in the development of research objectives
Generate metrics and tools to monitor progress and accountability
Develop a diverse portfolio with funds distributed across stages
Combine existing therapies and new technologies
Thank you for your interest in contacting us. Please fill out the form with your inquiry or feedback, and our team will promptly respond to assist you.
